US Bancorp DE Has $174,000 Stock Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

US Bancorp DE lessened its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 58.2% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 9,632 shares of the company’s stock after selling 13,404 shares during the quarter. US Bancorp DE’s holdings in Teva Pharmaceutical Industries were worth $174,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in TEVA. New Covenant Trust Company N.A. purchased a new stake in shares of Teva Pharmaceutical Industries in the first quarter valued at $28,000. EntryPoint Capital LLC purchased a new stake in Teva Pharmaceutical Industries in the 1st quarter worth about $30,000. UMB Bank n.a. boosted its position in Teva Pharmaceutical Industries by 555.6% during the 3rd quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock worth $44,000 after acquiring an additional 2,067 shares during the period. Beach Investment Counsel Inc. PA purchased a new position in Teva Pharmaceutical Industries during the 2nd quarter valued at about $48,000. Finally, Byrne Asset Management LLC purchased a new position in Teva Pharmaceutical Industries during the 2nd quarter valued at about $52,000. Institutional investors and hedge funds own 54.05% of the company’s stock.

Wall Street Analysts Forecast Growth

TEVA has been the subject of several research reports. Barclays raised their price target on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a report on Wednesday, October 23rd. UBS Group lifted their target price on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. StockNews.com raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. Finally, JPMorgan Chase & Co. lifted their price objective on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research report on Monday, October 21st. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $19.67.

Teva Pharmaceutical Industries Stock Down 1.1 %

Shares of Teva Pharmaceutical Industries stock opened at $16.75 on Friday. Teva Pharmaceutical Industries Limited has a 12-month low of $8.64 and a 12-month high of $19.31. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.57. The stock has a 50 day moving average price of $17.84 and a two-hundred day moving average price of $17.20. The stock has a market capitalization of $18.98 billion, a P/E ratio of -19.71, a PEG ratio of 1.34 and a beta of 0.87.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.